ENTX

Entera BioF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$1.90

Analysis reference price unavailable

Analysis 2026-05-02 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$1.00

Analysis reference price unavailable

Analysis 2026-05-02 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.55

Analysis reference price unavailable

Analysis 2026-05-02 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-05-02

AI commentary

Primary-source tone is constructive around EB613 and the April financing, but the checked evidence still reads as a cautious monitoring setup rather than a confirmed inflection. Reviewed IR materials show March-April 2026 milestone activity, yet no confirmed FDA-response follow-up was found in the checked sources as of May 2, 2026, no meaningful recent trusted-news or analyst-revision set was present to strengthen conviction, and the available peer set is too loose for a standard-conviction relative view.

RankAlpha Sentiment Codex - 2026-05-02

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-05-03eventPending FDA feedback on the streamlined EB613 Phase 3 amendmentHigh impact

Entera said it submitted a streamlined Phase 3 protocol, SAP, and extension synopsis for EB613 on March 4, 2026 and anticipated FDA feedback within 60 days; the March 27 business update still pointed to feedback in late April 2026. A confirmed FDA response or protocol alignment would be the cleanest near-term de-risking event, but no checked primary follow-up was found in the reviewed materials as of May 2, 2026 [#PR-2026-03-04] [#10-K-2026-03-27].

2026-11-15catalystEB613 Phase 3 initiation remains the main value driver for late 2026High impact

Management said the planned EB613 study could start in late 2026, with a 750-patient design and topline in 2H 2028, and the April 2026 financing was earmarked to support Phase 3 initiation. However, the 10-K also said existing cash was sufficient only through the middle of Q3 2026 excluding Phase 3 initiation, so actual study start would simultaneously confirm execution and reduce financing doubt [#PR-2026-03-04] [#8-K-2026-04-03] [#10-K-2026-03-27].

2026-12-15catalystEB612 pre-IND/IND progress offers a secondary pipeline checkHigh impact

Beyond EB613, Entera said it intended to accelerate its oral long-acting PTH program for hypoparathyroidism and expected an IND filing in late 2026 with OPKO-related support. This is a real pipeline milestone, but it is clearly secondary to EB613 for current valuation and does not remove near-term funding or execution risk [#10-K-2026-03-27].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-02 • Updated nightlySource: Internal modelMethodology